ASH 2019: Older Age Should Not Be Barrier to Transplantation for Multiple Myeloma
Read it now on PracticeUpdate.com
Related Articles
Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups
María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma
Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups
María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma
Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups
María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma
5th EUROPEAN MYELOMA NETWORK MEETING
Dear colleagues and fri ends, It is our great pleasure to invite you to attend the 5th EMN meeting – EMN2024 – that will take…
Ravi Vij in Discussion with Dr. Jeffrey Zondor MD, on Treating Amyloidosis at @mycancerhaven
Ravi Vij in Discussion with Dr. Jeffrey Zondor MD, Professor of Medicine, Department of Oncology, Wayne State University School of Medicine, Detroit, MI.#amy…
Cardinals Hire Pat Kelsey to Lead Men’s Basketball Program – University of Louisville Athletic
Pat Kelsey, a proven program builder who’s won nearly 70% of his career games, has been named the new men’s basketball head coach at the…
Throwing Bones – Blood Cancer Nonprofit Organization
Be cancer active! Throwing Bones is a blood cancer nonprofit organization fighting to help bring awareness and treatment to blood cancer by promoting fitness.
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
Abstract. Immunomodulatory Drugs (IMiDs) are a backbone therapy for multiple myeloma (MM). Despite their efficacy, most patients develop resistance, and the mechanism(s) are not fully…